Adherence to surveillance among patients with superficial bladder cancer

Journal of the National Cancer Institute

Volumn 95, Issue 8, 2003, Pages 588-597

  Schrag, Deborah ^a   Hsieh, Lillian J ^a   Rabbani, Farhang ^a   Bach, Peter B ^a   Herr, Harry ^a   Begg, Colin B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; DATA BASE; DEMOGRAPHY; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEALTH PROGRAM; HISTOPATHOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICARE; NEGRO; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT INFORMATION; PERIODIC MEDICAL EXAMINATION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; STATISTICAL ANALYSIS; TUMOR DIFFERENTIATION; URBAN AREA;

EID: 0037688066     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.8.588     Document Type: Article

References (41)

1. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7.
2. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-6.
3. Holmang S, Hedelin H, Anderstrom, C, Holmberg E, Busch C, Johansson SL. Recurrence and progression in low grade papillary urothelial tumors. J Urol 1999;162:702-7.
4. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001;165:1124-8; discussion 8-30.
5. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002;167:1634-7.
6. Cookson MS, Sarosdy MF. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 1992; 148:797-801.
7. Prout GR Jr, Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J Urol 1992;148:1413-9.
8. Torti FM, Lum BL. The biology and treatment of superficial bladder cancer. J Clin Oncol 1984;2:505-31.
9. Lamm DL. Re: bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). J Urol 2000;163:1890-1.
10. Morey SS. American Urological Association issues guidelines on the management of bladder cancer. Am Fam Physician 2000;61:3734, 3736.
11. Scher H, Bahnson R, Cohen S, Eisenberger M, Herr H, Kozlowski J, et al. NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology (Huntingt) 1998;12:225-71.
12. Prout GR Jr. Bladder cancer. J Urol 1982;128:284.
13. Davis JW, Sheth SI, Doviak MJ, Schellhammer PF. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol 2002;167: 494-500; discussion 501.
14. Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995;153:1823-6; discussion 1826-7.
15. Morris SB, Shearer RJ, Gordon EM, Woodhouse CR. Superficial bladder cancer: timing of check cystoscopies in the first year. Br J Urol 1993;72: 446-8.
16. Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol 1997;15:84-8.
17. Herr HW, Laudone VP, Whitmore WF Jr. An overview of intravesical therapy for superficial bladder tumors. J Urol 1987;138:1363-8.
18. Herr HW. Outpatient flexible cystoscopy and fulguration of recurrent superficial bladder tumors. J Urol 1990;144:1365-6.
19. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). Available at: http://www.seer.cancer.gov. [Last accessed 2/22/03.]
20. Percy C, Van Holton V, Muir CE. International classification of diseases for oncology. 2nd ed. Geneva (Switzerland): World Health Organization; 1990.
21. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732-48.
22. International classification of diseases, 9th revision, ICD-9-CM. Chicago (IL): American Medical Association Publications; 2000.
23. Current procedural terminology 1999. Chicago (IL): American Medical Association Publications; 1999.
24. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9; discussion 1081-90.
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
26. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53: 1258-67.
27. Hosmer DW, Lemeshow S. Applied logistic regression. New York (NY): John Wiley & Sons; 1989. p. 241-3.
28. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001;93:850-7.
29. Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000; 117:1239-46.
30. Smedley BD, Stith AY, Nelson AR, editors. Unequal treatment: confronting racial and ethnic disparities in health care. Washington (DC): National Academy Press; 2002. Available at: www.nap.edu/books/030908265X/html/. [Last accessed 2/22/03.]
31. Institute of Medicine, editor. Coverage matters: insurance and health care. Washington (DC): National Academy Press; 2001. p. 53-6.
32. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999;341:1198-205.
33. Kilbridge K, Kuntz K, Kagan A, Loughlin K, Weinstein M, Kantoff P, et al. The cost-effectiveness of frequent follow-up in superficial transitional cell cancer of the bladder. Philadelphia (PA): ASCO. 1996. Available at http://www.asco.org (click on "Meetings and Education", "Abstracts", "Search All Abstracts", then type "Kilbridge K" in the author query field). [Last accessed 2/23/03.]
34. Hsia DC, Krushat WM, Fagan AB, Tebbutt JA, Kusserow RP. Accuracy of diagnostic coding for Medicare patients under the prospective-payment system. N Engl J Med 1988;318:352-5.
35. Iezzoni LI. Assessing quality using administrative data. Ann Intern Med 1997;127:666-74.
36. Lloyd SS, Rissing JP. Physician and coding errors in patient records. JAMA 1985;254:1330-6.
37. McCarthy EP, Iezzoni LI, Davis RB, Palmer RH, Cahalane M, Hamel MB, et al. Does clinical evidence support ICD-9-CM diagnosis coding of complications? Med Care 2000;38:868-76.
38. Hurtado MP, Swift EK, Corrigan JM, editors. Envisioning the national health care quality report. Washington (DC): National Academy Press; 2001. p. 1-18.
39. Hewitt M, Simone J, editors. Ensuring quality cancer care. Washington (DC): National Academy Press; 1999. p. 1-12. Available at: www.nap.edu/books/0309064805/html/. [Last accessed 2/22/03.]
40. Committee on Quality of Health Care in America. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington (DC): National Academy Press; 2001. p. 1-22. Available at: http://www.nap.edu/books/0309072808/html/. [Last accessed 2/22/03.]
41. Cancer staging manual. Urinary bladder staging. New York (NY): Springer-Verlag; 2002. p. 335.